CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.3B, above the global median of $1.18B
- PositionCurrent ratio is 24.57×, higher than 95% of its Biotechnology peers (median 5.28×)
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.48%
Annual Rate
CNY 0.10Paid annual
Payout Ratio
100.0%High
Last Ex-Dividend
Jun 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.74BCNY1.30B · vs all stocks (USD)
Trailing P/E
209.80xvs Biotechnology peers
Revenue (TTM)
1.36BCNY203.12M · vs all stocks (USD)
Profit Margin
3.14%vs Biotechnology peers
Beta
0.4240xvs all stocks
52-Week Change
-22.33%vs all stocks
Market Capitalization
8.74BCNY1.30B · vs all stocks (USD)
Enterprise Value
3.42BCNY510.64M · vs all stocks (USD)
Trailing P/E
209.80xvs Biotechnology peers
Forward P/E
38.85xvs Biotechnology peers
Price to Sales (TTM)
6.42xvs Biotechnology peers
Price to Book (MRQ)
0.9230xvs Biotechnology peers
Enterprise to Revenue
2.51xvs Biotechnology peers
Enterprise to EBITDA
17.97xvs Biotechnology peers
Gross Margin
74.37%vs Biotechnology peers
Profit Margin
3.14%vs Biotechnology peers
Operating Margin
11.42%vs Biotechnology peers
Return on Assets (TTM)
-0.10%vs Biotechnology peers
Return on Equity (TTM)
0.46%vs Biotechnology peers
Revenue (TTM)
1.36BCNY203.12M · vs all stocks (USD)
Revenue per Share (TTM)
3.27CNYUpdated Sep 22, 2026Quarterly Revenue Growth
15.90%vs Biotechnology peers
Gross Profit (TTM)
913.37MCNY136.34M · vs all stocks (USD)
EBITDA (TTM)
426.91MCNY63.73M · vs all stocks (USD)
Net Income (TTM)
42.78MCNY6.39M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-29.70%vs Biotechnology peers
Operating Cash Flow (TTM)
285.15MCNY42.56M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-61.64MCNY-9.20M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1000CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
0.48%vs all stocks
Payout Ratio
100.00%vs Biotechnology peers
Revenue
1.39BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
286.82MCNYFY2025 · Dec 31, 2025Gross Profit
1.10BCNYFY2025 · Dec 31, 2025Operating Income
196.98MCNY29.40M · vs all stocks (USD)
Pre-tax Income
169.60MCNYFY2025 · Dec 31, 2025Income Tax Expense
37.81MCNYFY2025 · Dec 31, 2025Net Income
131.79MCNYFY2025 · Dec 31, 2025EBIT
171.03MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
426.91MCNYFY2025 · Dec 31, 2025Research & Development
294.04MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
335.18MCNYFY2025 · Dec 31, 2025Other Operating Expenses
23.44MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
37.18MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.43MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3200CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
411.84MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
411.84MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
131.79MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
103.00MCNYFY2025 · Dec 31, 2025Free Cash Flow
-205.08MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
4.37BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
131.79MCNYFY2025 · Dec 31, 2025Other Non-cash Items
4.06MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
18.39MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-51.24MCNYFY2025 · Dec 31, 2025Capital Expenditures
-308.08MCNYFY2025 · Dec 31, 2025Purchase of Investments
-4.59BCNYFY2025 · Dec 31, 2025Sale of Investments
4.77BCNYFY2025 · Dec 31, 2025Other Investing Activity
-357.00KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-126.88MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-329.23MCNYFY2025 · Dec 31, 2025Other Financing Charges
-17.30MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-346.53MCNYFY2025 · Dec 31, 2025Shares Outstanding
416.45MSharesUpdated Sep 22, 2026Float Shares
177.56MSharesUpdated Sep 22, 2026% Held by Insiders
57.58%vs all stocks
% Held by Institutions
0.79%vs all stocks
Total Cash (MRQ)
5.12BCNY764.98M · vs all stocks (USD)
Total Cash per Share (MRQ)
12.47CNYUpdated Sep 22, 2026Total Debt (MRQ)
7.12MCNY1.06M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0008xvs Biotechnology peers
Current Ratio (MRQ)
24.57xvs Biotechnology peers
Book Value per Share (MRQ)
22.73CNYUpdated Sep 22, 2026Total Assets
9.75BCNY1.45B · vs all stocks (USD)
Total Current Assets
6.79BCNYFY2025 · Dec 31, 2025Total Liabilities
392.05MCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.96BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
91.41MCNYFY2025 · Dec 31, 2025Total Current Liabilities
300.63MCNYFY2025 · Dec 31, 2025Cash
4.30BCNYFY2025 · Dec 31, 2025Cash Equivalents
60.21MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
4.36BCNYFY2025 · Dec 31, 2025Other Short-term Investments
850.47MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.05BCNYFY2025 · Dec 31, 2025Inventory
474.39MCNYFY2025 · Dec 31, 2025Accounts Payable
172.95MCNYFY2025 · Dec 31, 2025Short-term Debt
4.60MCNYFY2025 · Dec 31, 2025Other Current Liabilities
12.16KCNYFY2025 · Dec 31, 2025Long-term Debt
4.77MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
11.21MCNYFY2025 · Dec 31, 2025Common Stock (Book)
416.45MCNYFY2025 · Dec 31, 2025Retained Earnings
3.86BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
9.35BCNY1.40B · vs all stocks (USD)
Treasury Stock
160.78MCNYFY2025 · Dec 31, 202552-Week Low
18.91CNYUpdated Sep 22, 202652-Week High
28.43CNYUpdated Sep 22, 202652-Week Change
-22.33%vs all stocks
Beta
0.4240xvs all stocks
50-Day MA
20.33CNYUpdated Sep 22, 2026200-Day MA
23.11CNYUpdated Sep 22, 2026Avg 10-Day Volume
1.50MSharesUpdated Sep 22, 2026Avg 30-Day Volume
2.17MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
0.1000CNYUpdated Sep 22, 20268 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Retained Earnings Heavy With Elevated Payout
Profits kept in the business fund much of what it owns, and it now pays out most of what it earns.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Where is this company structurally exposed?
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 24.57×, higher than 95% of its Biotechnology peers (median 5.28×)Significant
Current ratio: 24.57Industry median: 5.28Industry P95: 22.31Peers compared: 193
P/E ratio is 209.8×, higher than 95% of its Biotechnology peers (median 35.29×)Significant
P/E ratio: 209.8Industry median: 35.29Industry P95: 160.274Peers compared: 193
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)Notable
Debt-to-equity: 0.00Industry median: 0.12Industry P5: 0.00Peers compared: 193
Price-to-book is 0.92×, lower than 95% of its Biotechnology peers (median 4.62×)Notable
Price-to-book: 0.92Industry median: 4.62Industry P5: 1.32Peers compared: 193
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.74Profit Margin: 0.03
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.3B, above the global median of $1.18BNotable
Market cap (USD): 1,304,190,051.67Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Bio-Thera Solutions Ltd.
Tier 1ProductionApproval-Gated PipelineRule
North China Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sinocare Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Weigao Orthopaedic Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Hisun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vcanbio Cell & Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Akums Drugs & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Damora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Imeik Technology Development Co., Ltd.
6 interpretationsHigh Retained Earnings With Profitability And EquityLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedRetained Earnings Heavy With Elevated PayoutLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Foshan Haitian Flavouring & Food Co., Ltd.
6 interpretationsRetained Earnings Heavy With Elevated PayoutLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh Retained Earnings With Profitability And EquityCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated
Energy Recovery Inc.
5 interpretationsHigh Retained Earnings With Profitability And EquityLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity